The shares of this pharma stock under the ‘small-cap’ category rose up to 12 percent today after the entity announced Q1FY23-24 results. In the past six months, the scrip has gained close to 40 percent from Rs 705.40 to the current price level.
With a market capitalization of Rs 7,400 crores, the stocks of Caplin Point Laboratories Limited opened their trading hour on Tuesday at Rs 896 and currently trade at Rs 972. The company’s scrip witnessed an intra-day high, also recorded as the fresh 52-week high mark, of Rs 1,003.80 indicating a gain of around 12 percent compared to the previous closing levels of Rs 896 apiece.
Such stock price movements were observed today after the company, through a regulatory filing with the BSE dated 7th August 2023, announced financial results for the quarter ending June 2023.
The company’s Board also recommended a Final Dividend of Rs 2.50 per equity share, i.e., a 125 percent payout compared to a Face Value of Rs 2 per share. The payment of the same is subject to approvals from the company’s shareholders.
On a sequential basis, there has been a marginal increase in the basic operational indicators such as revenues and after-tax profits. The former rose from Rs 389 crores during Q4FY22-23 to Rs 395 crores during Q1FY23-24, and, the latter moved up from Rs 101 crores to Rs 104 crores keeping the timeframe the same.
Moreover, the company, on a YoY basis, reported an increase in operating revenues from Rs 346 crores during Q1FY22-23 to Rs 395 crores during Q1FY23-24. Moreover, the after-tax profits, during the same time horizon, went up from Rs 86 crores to Rs 104 crores representing an increase of 21 percent.
According to the June 2023 quarter, the shareholding pattern data showcases the Promoters holding a 70.63 percent stake, and the Foreign Institutional Investors (FIIs) holding a 2.68 percent stake in the company.
Caplin Point Laboratories Limited is a pharmaceutical company based in India that is engaged in the business of manufacturing as well as marketing its products, some of which include capsules, tablets, dry powder, liquid orals, and many more.
Written by Amit Madnani
